Xihuang Pill unites gemcitabine on the clinical benefit in advanced pancreatic carcinoma / 中成药
Chinese Traditional Patent Medicine
; (12): 13-15, 2010.
Article
de Zh
| WPRIM
| ID: wpr-433200
Bibliothèque responsable:
WPRO
ABSTRACT
AIM:To evaluate treatment value of Xihuang Pill combined gemeitabine for advanced pancreatic cancer patients.METHODS:Thirty-two patients with advanced pancreatic cancer were randomly divided into A group and B group,treated with gemcitabine chemotherapy and traditional Chinese medicine Xihuang Pill+chemotherapy treatment,respectively.The changes of the solid tumor,serum CA19-9,physical status,clinical symptoms and toxicity were observed.RESULTS:B group(Xihuang Pill combined with gemcitabine)clinical return ratio (CR+PR+NC)was better than A group(gemcitabine).There was significant difference between two groups in the reduction of serum CA19-9 level,Karuofsky score increased,the rate of symptom improvement,Leukopenia reduction(P<0.05).CONCLUSION:Integrating Xihuang Pill and gemcitabine in the treatment of advanced pancreatic cancer:delaying of tumor growth,reducing of CA19-9 level,improving of the clinical symptoms and life quality of patients,reducing of neutropenia in patients(chemotherapy-induced toxicity),shows good clinical benefit response.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Chinese Traditional Patent Medicine
Année:
2010
Type:
Article